Research

rs4680 — COMT Val158Met

Dopamine/catecholamine breakdown — affects stress response and methyl donor tolerance

Established Risk Factor

Details

Gene
COMT
Chromosome
22
Protein change
p.Val158Met
Consequence
Missense
Inheritance
Codominant
Clinical
Risk Factor
Evidence
Established
Chip coverage
v3 v4 v5

Population Frequency

GG
25%
AG
50%
AA
25%

Ancestry Frequencies

european
52%
south_asian
45%
latino
42%
african
30%
east_asian
29%

COMT Val158Met — The Warrior/Worrier Gene

COMT (catechol-O-methyltransferase) 11 COMT methylates and inactivates catechol-containing compounds including dopamine, estrogens, and certain drugs is an enzyme that breaks down catecholamines — dopamine, norepinephrine, and epinephrine — by adding a methyl group from SAM. The Val158Met variant (rs4680) is one of the most fascinating genetic variants because it doesn't have a clear "good" or "bad" allele. Instead, each version confers different cognitive and behavioral trade-offs.

The Mechanism

The A allele (Met) 22 Val158Met: valine-to-methionine substitution at position 158 of the enzyme (p.Val158Met) produces an enzyme that works 3-4 times slower than the G allele (Val) version. Methionine at position 158 makes the enzyme thermolabile, reducing its catalytic efficiency at body temperature. Slower COMT means dopamine and other catecholamines persist longer in the prefrontal cortex, the brain region responsible for working memory, planning, and executive function 33 The prefrontal cortex is uniquely dependent on COMT for dopamine clearance because it lacks the dopamine transporter found in other brain regions.

Warrior vs. Worrier

The GG (Val/Val) "warrior" genotype breaks down dopamine quickly, resulting in lower prefrontal dopamine levels. Warriors perform better under stress and pressure but may have less optimal baseline cognitive performance. The AA (Met/Met) "worrier" genotype maintains higher dopamine levels, leading to better cognitive performance in calm conditions but greater vulnerability to stress and anxiety. This cognitive trade-off was demonstrated in a landmark study by Egan et al.44 landmark study by Egan et al.
Egan MF et al. COMT Val158Met effects on prefrontal cortex function, 2001
.

Pain and Opioid Response

COMT genotype significantly affects pain sensitivity and opioid response. The Zubieta landmark study55 Zubieta landmark study
Zubieta JK et al. COMT Val158Met affects mu-opioid neurotransmitter responses to pain, 2003
showed that Met/Met individuals have diminished mu-opioid responses to pain. A study on cancer patients66 study on cancer patients
Rakvag TT et al. COMT Val158Met influences morphine requirements in cancer pain patients, 2005
found that Val/Val patients needed 63% higher morphine doses than Met/Met patients. A meta-analysis77 meta-analysis
Chen YC et al. COMT Val158Met and postoperative opioid consumption, 2018
confirmed reduced opioid consumption in Met carriers.

The Methylation Connection

COMT uses SAM as its methyl donor, directly linking it to the methylation cycle. Slow COMT (AA) individuals are more sensitive to methyl donors like methylfolate, methylB12, and TMG 88 Trimethylglycine (betaine): a potent methyl donor derived from choline that feeds into the methylation cycle (trimethylglycine). Excess methyl groups can overstimulate an already slow COMT pathway, causing anxiety, irritability, and insomnia. This is why some people feel worse on high-dose methylated B vitamins.

Practical Implications

If you are AA (slow COMT), be cautious with methyl donor supplements. Start with low doses and increase gradually. Folinic acid and hydroxocobalamin are gentler alternatives to methylfolate and methylcobalamin. Glycine (2-4g) can help buffer excess methyl groups. If you are GG (fast COMT), you generally tolerate methyl donors well and may even benefit from them. This variant is key to personalizing your methylation support strategy.

Interactions

COMT interacts with MTHFR (rs1801133) — MTHFR determines methylfolate production while COMT determines tolerance. Someone with both MTHFR AA (low methylfolate) and COMT AA (slow methylation) faces a complex supplementation challenge.

Drug Interactions

morphine dose_adjustment literature
tramadol dose_adjustment literature

Nutrient Interactions

folate altered_metabolism
vitamin B12 altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant:

AG “Balanced (Intermediate)” Intermediate

Intermediate COMT (Val/Met) — balanced

You have intermediate COMT activity, balancing between the fast and slow extremes. This is the most common genotype, shared by about 50% of Europeans.

GG “Warrior (Fast)” Fast

Fast COMT (Val/Val) — the "Warrior" genotype

You have the "warrior" COMT genotype. Your enzyme rapidly breaks down dopamine and other catecholamines. This means:

  • Lower baseline dopamine in the prefrontal cortex
  • Better stress tolerance under pressure
  • You can handle methyl donors (B vitamins, SAMe) without issue
  • May benefit from things that boost dopamine

About 25% of Europeans share this genotype.

AA “Worrier (Slow)” Slow Caution

Slow COMT (Met/Met) — the "Worrier" genotype

You have the "worrier" COMT genotype. Your enzyme slowly breaks down dopamine and catecholamines. This means:

  • Higher baseline dopamine in the prefrontal cortex
  • Better cognitive performance in calm conditions
  • More sensitive to stress
  • CAUTION with high-dose methyl donors (TMG, methylfolate)

About 25% of Europeans share this genotype.

Key References

PMID: 12595695

Zubieta et al. landmark study showing COMT Val158Met affects mu-opioid neurotransmitter responses to pain

PMID: 15927391

COMT Val158Met influences morphine requirements in cancer pain patients

PMID: 29402857

Meta-analysis of COMT Val158Met and postoperative opioid consumption

PMID: 22132136

COMT Val158Met affects brain responses to repeated painful stimuli via fMRI

PMID: 11556918

Egan et al. COMT Val158Met effects on prefrontal cortex function and working memory

PMID: 17156920

Joint effects of COMT and OPRM1 on morphine dose requirements in cancer patients